EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Selective killing of castration‐resistant prostate cancer cells by formycin A via the ATF4 – CHOP axis

Tomoki Takei, Yuki Hamamura, Hiroshi Hongo iD, Etsu Tashiro iD, Masaya Imoto iD, Takeo Kosaka iD, Mototsugu Oya iD

Cancer Science · 2024

DOI: 10.1111/cas.16349 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Tomoki Takei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University, Yokohama, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Activating Transcription Factor 4, Transcription Factor CHOP, Mice, Nude. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Grants-in-Aid for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer is initially androgen‐dependent but often relapses to an androgen‐independent state called castration‐resistant prostate cancer (CRPC). Currently approved therapies have limited efficacy against CRPC, highlighting the need for novel therapeutic strategies. To address this need, we conducted a drug screen in our previously established aggressive CRPC cell model. We found that formycin A induced cell death in CRPC model cells but not in parental prostate cancer cells. In addition, formycin A upregulated death receptor 5 through the induction of endoplasmic reticulum stress, activating the “extrinsic” apoptosis pathway in CRPC model cells. Moreover, formycin A showed in vivo antitumor efficacy against CRPC xenografts in castrated nude mice. Thus, our findings highlight the potential of formycin A as a CRPC therapeutic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantActivating Transcription Factor 4Transcription Factor CHOPMice, NudeXenograft Model Antitumor AssaysEndoplasmic Reticulum StressApoptosisMaleHumansAnimalsMiceCell Line, TumorSignal Transduction

Stichwörter der Autor:innen

CRPCER stressantitumor activitydeath receptor 5formycin A

Substanzen

Activating Transcription Factor 4Transcription Factor CHOPATF4 protein, humanDDIT3 protein, human

Autor:innen und Institutionen

  • Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University, Yokohama, Japan.
  • Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Department of Urology, Keio University School of Medicine, Tokyo, Japan.
  • Laboratory of Biochemistry, Showa Pharmaceutical University, Tokyo, Japan.

ORCID-Profile: Hiroshi Hongo, Etsu Tashiro, Masaya Imoto, Takeo Kosaka, Mototsugu Oya

Förderung

  • Grants-in-Aid for Scientific Research

Zitieren

APA

Takei, T., Hamamura, Y., Hongo, H., Tashiro, E., Imoto, M., Kosaka, T., & Oya, M. (2024). Selective killing of castration‐resistant prostate cancer cells by formycin A via the ATF4 – CHOP axis. Cancer Science. https://doi.org/10.1111/cas.16349

Vancouver

Takei T, Hamamura Y, Hongo H, Tashiro E, Imoto M, Kosaka T, et al. Selective killing of castration‐resistant prostate cancer cells by formycin A via the ATF4 – CHOP axis. Cancer Science. 2024. doi:10.1111/cas.16349

BibTeX
@article{Takei2024,
  author = {Takei, Tomoki and Hamamura, Yuki and Hongo, Hiroshi and Tashiro, Etsu and Imoto, Masaya and Kosaka, Takeo and Oya, Mototsugu},
  title = {Selective killing of castration‐resistant prostate cancer cells by formycin A via the ATF4 – CHOP axis},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16349}
}
Kostenlos starten →